Zealand Pharma: promising results of a phase 2a study.
(CercleFinance.com) - On Thursday Denmark's Zealand Pharma disclosed positive results from a phase 2a clinical safety trial using dasiglucagon for the prevention and treatment of low blood sugar in type-1 diabetes.
The trial - which included 10 adult patients with type-1 diabetes using an automated pump system - showed that dasiglucagon, together with insulin, was observed to be effective in controlling blood sugar.
Zealand Pharma and its partner Beta Bionics are now looking forward to initiate a phase 2b trial with dasiglucagon.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The trial - which included 10 adult patients with type-1 diabetes using an automated pump system - showed that dasiglucagon, together with insulin, was observed to be effective in controlling blood sugar.
Zealand Pharma and its partner Beta Bionics are now looking forward to initiate a phase 2b trial with dasiglucagon.
Copyright (c) 2017 CercleFinance.com. All rights reserved.